ImageneBio Inc

IMA

市值 US$4586萬

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on September 30, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 90,775 restricted stock units (“RSUs”) and 32,725 non-qualified stock options (“NSOs”) to three newly hired non-executive employees. The foregoing inducement awards were granted as inducements material to the new employees entering into employment with Imagene in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the Company's 2025 Equity Inducement Plan and the applicable equity award agreements.

SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 14, 2026, and management will participate in one-on-one meetings.

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that on August 14, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of 79,000 restricted stock units (“RSUs”) and 56,525 non-qualified stock options (“NSOs”) to three newly hired non-executive employees. Additionally, the Compensation Committee granted inducement awards consisting of 65,000 RSUs and 56,000 NSOs to Yanina Grant-Huerta, our Chief Financial Officer. The foregoing inducement awards were granted as inducements material to the new employees entering into employment with Imagene in accordance with Nasdaq Listing Rule 5635(c)(4), and are subject to the terms and conditions of the Company's 2025 Equity Inducement Plan and the applicable equity award agreements. Ms. Grant-Huerta was also granted 39,000 restricted stock units under the Company's 2025 Equity Incentive Plan.

SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended June 30, 2026, and provided a company update. Company Highlights Olevaprubart, also known as IMG-007, the potential first-in-class therapeutic targeting the OX40 pathway, is a non-T cell-depleting, ADCC-silenced, anti-OX40 receptor antagonist with an extended half-life.

Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies

WASHINGTON--(BUSINESS WIRE)-- #Education--The Independent Medical Alliance (IMA) today announced the official launch of IMA Academy, a new medical education platform designed to provide healthcare professionals with expert-led, evidence-first education that is independent, transparent, and free from institutional and commercial influence. Available at academy.imahealth.org, IMA Academy represents a major milestone in the organization's mission to restore trust in medicine by expanding access to high-quality.

SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings.

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program, IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life. Company Highlights In April 2026, the Company completed a private placement for gross proceeds of approximately $30 million led by new investor, Coastlands Capital, with participation from Trails Edge Capital Partners and existing investors Omega Funds and OrbiMed, among others.

ImageneBio is a clinical-stage biopharmaceutical company focused on developing therapeutics for immunological, autoimmune and inflammatory diseases.

SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA)(“Imagene” or the “Company”) today announced it has entered into a definitive securities purchase agreement with certain institutional investors in a private placement that is expected to result in gross proceeds of approximately $30 million to Imagene, before deducting placement agent fees and other expenses. The company intends to use the proceeds from the offering to support further development of IMG-007 in alopecia areata and late-stage development activities in atopic dermatitis.